A multicenter randomized trial showed that adding linear ablation and ethanol infusion to pulmonary vein isolation (PVI) led to better management of persistent atrial fibrillation (AF) compared to PVI alone. The trial resulted in a 70.7% freedom from AF recurrences without anti-arrhythmia drugs in patients with the additional treatments, as opposed to 61.5% in the PVI-only group. The study demonstrated a 27% risk reduction in the primary endpoint with the add-ons compared to PVI alone. While the outcomes are promising, the study population had limitations and further research is needed to determine the long-term efficacy of these additional treatments for persistent AF.
Source link
PVI Add-Ons Provide Better Control of Persistent AF
